Myopericarditis is a rare complication of vaccination. However, there have been increasing reports of myopericarditis following COVID-19 vaccination, especially among adolescents and young adults. We aimed to characterise the incidence of myopericarditis following COVID-19 vaccination, and compare this with non-COVID-19 vaccination.
Methods
We did a systematic review and meta-analysis, searching four international databases from Jan 1, 1947, to Dec 31, 2021, for studies in English reporting on the incidence of myopericarditis following vaccination (the primary outcome). We included studies reporting on people in the general population who had myopericarditis in temporal relation to receiving vaccines, and excluded studies on a specific subpopulation of patients, non-human studies, and studies in which the number of doses was not reported. Random-effects meta-analyses (DerSimonian and Laird) were conducted, and the intra-study risk of bias (Joanna Briggs Institute checklist) and certainty of evidence (Grading of Recommendations, Assessment, Development and Evaluations approach) were assessed. We analysed the difference in incidence of myopericarditis among subpopulations, stratifying by the type of vaccine (COVID-19 vs non-COVID-19) and age group (adult vs paediatric). Among COVID-19 vaccinations, we examined the effect of the type of vaccine (mRNA or non-mRNA), sex, age, and dose on the incidence of myopericarditis. This study was registered with PROSPERO (CRD42021275477).
Findings
The overall incidence of myopericarditis from 22 studies (405 272 721 vaccine doses) was 33·3 cases (95% CI 15·3–72·6) per million vaccine doses, and did not differ significantly between people who received COVID-19 vaccines (18·2 [10·9–30·3], 11 studies [395 361 933 doses], high certainty) and those who received non-COVID-19 vaccines (56·0 [10·7–293·7], 11 studies [9 910 788 doses], moderate certainty, p=0·20). Compared with COVID-19 vaccination, the incidence of myopericarditis was significantly higher following smallpox vaccinations (132·1 [81·3–214·6], p<0·0001) but was not significantly different after influenza vaccinations (1·3 [0·0–884·1], p=0·43) or in studies reporting on various other non-smallpox vaccinations (57·0 [1·1–3036·6], p=0·58). Among people who received COVID-19 vaccines, the incidence of myopericarditis was significantly higher in males (vs females), in people younger than 30 years (vs 30 years or older), after receiving an mRNA vaccine (vs non-mRNA vaccine), and after a second dose of vaccine (vs a first or third dose).
Interpretation
The overall risk of myopericarditis after receiving a COVID-19 vaccine is low. However, younger males have an increased incidence of myopericarditis, particularly after receiving mRNA vaccines. Nevertheless, the risks of such rare adverse events should be balanced against the risks of COVID-19 infection (including myopericarditis).
Funding
None.
Results
Of 4919 studies, 156 full-text publications were reviewed. 22 observational studies totalling 405 272 721 vaccine doses were included in the meta-analysis (figure 1; appendix pp 10–17).
Hospitalizations within 14 days of vaccination among pediatric recipients of the live attenuated influenza vaccine, United States 2010-2012.
and three studies on a variety of non-COVID-19 vaccines (such as varicella; yellow fever; oral polio vaccine; measles, mumps, and rubella; meningococcal; diphtheria, pertussis, and tetanus; BCG; hepatitis; and typhoid; 5 488 732 doses).
Adverse events following vaccination in the French armed forces: an overview of surveillance conducted from 2002 to 2010.
Across the nine studies that specified the type of COVID-19 vaccine, 290 730 653 doses of mRNA vaccines and 51 969 677 doses of non-mRNA vaccines were administered. Definitions of pericarditis, myocarditis, and myopericarditis in individual studies or databases are summarised in the appendix (pp 10-17). The intra-study risk of bias and GRADE assessment are also provided in the appendix (pp 18–20); apart from one study,
Myopericarditis in young adults presenting to the emergency department after receiving a second COVID-19 mRNA vaccine.
all studies were of good quality (JBI score >7).
Figure 1Flow diagram of study identification and inclusion
The overall incidence of myopericarditis was 33·3 cases (95% CI 15·3–72·6) per million vaccine doses (high certainty, Egger’s test p=0·12; figure 2; appendix p 21). Sensitivity analyses excluding studies with high risks of bias and databases found that the pooled incidence of myopericarditis for COVID-19 and non-COVID-19 vaccines did not change significantly (appendix p 22).
Figure 2Incidence of myopericarditis following vaccination in studies investigating COVID-19 and non-COVID-19 vaccines
The pooled incidence of myopericarditis following vaccination was 18·2 cases per million doses of COVID-19 vaccine and 56·0 cases per million doses of non-COVID-19 vaccine (p=0·20).
The overall incidence of myopericarditis in the general population did not differ significantly after receipt of COVID-19 vaccines (18·2 cases [10·9–30·3] per million doses, high certainty) compared with non-COVID-19 vaccines (56·0 [10·7–293·7], moderate certainty, p=0·20; figure 2). Comparing COVID-19 vaccines with each type of non-COVID-19 vaccine found a significant difference between subpopulations (global pvs COVID-19 vaccines), 1·3 (0·0–884·1) per million doses of influenza vaccine (p=0·43), and 57·0 (1·1–3036·6) per million doses for studies reporting on a variety of vaccines (p=0·58; appendix p 23). Between the adult subgroup (26·0 cases [11·8–57·4] per million doses; 298 508 729 doses, 14 studies) and paediatric subgroup (18·4 [4·7–72·9]; 12 145 663 doses, six studies), the incidence of myopericarditis did not differ significantly (p=0·67; appendix p 24).
Among COVID-19 vaccines, the incidence of myopericarditis was significantly higher (p=0·0010) among those who received mRNA vaccines (22·6 cases [12·2–42·0] per million doses; 290 730 653 doses, nine studies; figure 3) than among those who received non-mRNA vaccines (7·9 [7·2–8·7]; 51 969 677 doses, three studies). Furthermore, incidence of myopericarditis was significantly higher in people younger than 30 years than in people aged 30 years or older, in those receiving a second dose of vaccination than in those receiving a first or third dose, and in males than in females (table; appendix pp 25–27). Among people younger than 30 years, the incidence of myopericarditis was approximately ten times higher in males than in females; for people older than 30 years, the incidence was around three times as high in males than in females (table; appendix pp 28–29). Further details on the demographic and clinical characteristics of patients with myopericarditis following vaccination are summarised in the appendix (pp 30–35). Time from vaccination to symptom onset was reported heterogeneously and hence these data were not pooled; nonetheless, most studies reported a window of 1–2 weeks before symptom presentation.
Figure 3Incidence of myopericarditis following vaccination in studies investigating mRNA and non-mRNA COVID-19 vaccines
The pooled incidence of myopericarditis following COVID-19 vaccination was 22·6 cases per million doses of mRNA vaccine and 7·9 cases per million doses of non-mRNA vaccine (p=0·0010).
TableSubgroup analyses among people who received COVID-19 vaccines
Forest plots of the studies included in these subgroup analyses are provided in the appendix (pp 25–29).
Meta-regression among five studies based on the age-stratified incidence of myopericarditis after COVID-19 vaccination using robust variance estimates found that age was negatively associated with myopericarditis (regression coefficient −0·069 [95% CI −0·094 to −0·045], p=0·0030, figure 4).
Strata-level meta-regression between age and logit-transformed robust-variance estimated incidence of myopericarditis following COVID-19 vaccination. Bubble sizes correspond to the weights of each study, which are computed as an inverse of the SE of the strata-level pooled estimate. Horizontal error bars correspond to the range of ages that each strata represents. Excluding people younger than 12 years, for whom few data were reported in the studies included, the incidence of myopericarditis increases as the mean age of each subgroup decreases.
A post-hoc analysis was done to investigate the incidence of myopericarditis in patients with COVID-19 (appendix pp 8–9, 36–37). Of 6181 studies, we assessed 393 full-text records and included 21 studies with 2 453 491 patients hospitalised with COVID-19 and had clinical or radiological suspicion for myopericarditis,
Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 Infection: results from the Big Ten COVID-19 Cardiac Registry.
Cardiac manifestations of COVID-19 in Shenzhen, China.
among whom there were 48 904 cases of myopericarditis (1·1% [95% CI 0·5–2·2]; appendix p 37).
Across all vaccines, the incidence of myocarditis was 16·0 cases (95% CI 8·2–31·2) per million doses (180 995 007 doses, seven studies, moderate certainty; appendix p 38). The incidence of myocarditis was significantly lower (p
Pericarditis had an incidence across all vaccines of 16·7 cases (5·8–48·0) per million doses (169 138 458 doses, seven studies, moderate certainty; appendix p 39), and did not differ significantly (p=0·64) between COVID-19 vaccines (10·1 [5·8–17·4], 166 286 019 doses, three studies) and non-COVID-19 vaccines (20·0 [1·2–328·5]; 2 852 439 doses, four studies; appendix p 39).
The pooled all-cause mortality following vaccination was 7·8 deaths (95% CI 1·8–34·7) per million doses (240 709 487 doses, ten studies, high certainty), and overall mortality was similar (p=0·93) between COVID-19 vaccines (8·4 [2·0–35·9]; 238 540 345 doses, five studies) and non-COVID-19 vaccines (7·2 [0·2–217·5]; 2 169 142 doses, five studies; appendix p 40).
Discussion
Our systematic review and meta-analysis shows that the incidence of myopericarditis in people who received COVID-19 vaccines was not significantly different from that in people who received non-COVID-19 vaccines in general, and was lower than that in people who received smallpox vaccines. Thus, the overall risk of myopericarditis appears to be no different for this very new group of vaccines against COVID-19 than for traditional vaccines against other pathogens. We also found that young men have a higher incidence of myopericarditis than others receiving mRNA COVID-19 vaccinations.
Among the general population, the background pre-pandemic incidence of myopericarditis varies greatly depending on age and sex,
Characterising the background incidence rates of adverse events of special interest for COVID-19 vaccines in eight countries: multinational network cohort study.
U.S. population-based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines.
In our meta-analysis, the incidence of myopericarditis following vaccination was 18·2 cases (95% CI 10·9–30·3; 8·9 cases of myocarditis and 10·1 cases of pericarditis) per million COVID-19 vaccine doses and 56·0 (10·7–293·7) per million doses of non-COVID-19 vaccines. The background incidence of myocarditis is 8·3–16·7 per million people per month
Trends in acute pericarditis hospitalizations and outcomes among the elderly in the USA, 1999–2012.
Notably, the specific incidence of myopericarditis after smallpox vaccination was significantly higher than after COVID-19 vaccines, and the incidence following influenza and other vaccines was similar to that following COVID-19 vaccines. The studies reporting on smallpox vaccination were primarily done in US military personnel, most of whom would be young men, and could account for the increased incidence of myopericarditis in smallpox vaccinees. The increased incidence of myopericarditis after non-COVID-19 vaccination might suggest that myopericarditis is a side-effect of the inflammatory processes induced by vaccination and is not uniquely a result of exposure to SARS-CoV-2 spike proteins through COVID-19 vaccination or infection. The risks of such infrequent adverse events are outweighed by the benefits of vaccination, which include a lower risk of infection, hospitalisation, severe disease, and death from COVID-19.
Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data.
Association between mRNA vaccination and COVID-19 hospitalization and disease severity.
In people aged 30 years or older, the incidence of post-vaccination myopericarditis was 2·9 cases (95% CI 1·8–4·7) per million vaccine doses. Being aware of a possible association between COVID-19 vaccination and myopericarditis, clinicians might have had an inherently lower threshold for investigating a patient with non-specific chest pain after COVID-19 vaccination, eventually leading to a diagnosis of myopericarditis. Additionally, given current robust vaccine surveillance systems and the fact that COVID-19 vaccines have received a much higher degree of scrutiny than previous vaccines, the possibility of relative under-reporting of adverse events following non-COVID-19 vaccinations cannot be excluded, despite mass vaccination of more than 6 billion people in the past year.
Our analysis found that myopericarditis was more common among those who were male and under the age of 30 years. The findings of our analysis appear to be concordant with the literature: male sex and younger age groups are more susceptible to myopericarditis after COVID-19 vaccination.
Previous studies have shown that myocarditis after the second dose of an mRNA COVID-19 vaccine occurs clinically in approximately one in 10 000 young males,
WHO COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS): updated guidance regarding myocarditis and pericarditis reported with COVID-19 mRNA vaccines.
US Centers for Disease Control and Prevention Clinical considerations: myocarditis and pericarditis after receipt of mRNA COVID-19 vaccines among adolescents and young adults.
while some have recommended avoiding strenuous exercise for 2 weeks following vaccination.
Ministry of Health Singapore Expert committee on COVID-19 vaccination: updates of assessment on myocarditis and pericarditis following vaccination with mRNA COVID-19 vaccines.
Several national guidelines also highlight the indications and contraindications for vaccine subtypes in this context.
Ministry of Health Singapore Expert committee on COVID-19 vaccination: updates of assessment on myocarditis and pericarditis following vaccination with mRNA COVID-19 vaccines.
Although the prognosis of this self-limiting condition is generally good, long-term outcomes for affected patients after 3 months and 6 months are currently awaited.
COVID-19-vaccination-induced myocarditis in teenagers: case series with further follow-up.
In people who received a COVID-19 vaccine, our results showed that myopericarditis was nearly four times as common in those receiving an mRNA vaccine than a non-mRNA vaccine and in those receiving their second dose of vaccine compared with a first or third dose. Similarly, a large study from Israel showed that mRNA COVID-19 vaccination was associated with a higher risk of myocarditis than the background population rate (risk ratio 3·24 [95% CI 1·55–12·44]). Over 90% of people with myocarditis after mRNA COVID-19 vaccination were male, with a median age of 25 years (IQR 20–34). The authors also highlighted an increased risk of myocarditis following COVID-19 infection (risk ratio 18·28 [95% CI 3·95–25·12]).
Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the Big Ten COVID-19 Cardiac Registry.
whereas our post-hoc analysis of myopericarditis in patients hospitalised with COVID-19 with radiological or clinical suspicion of myopericarditis found a prevalence of 1·1% (95% CI 0·5–2·2).
It is well recognised that such rare adverse reactions are unlikely to be identified in phase 3 trials because sample sizes are not large enough to capture these events. Following the initial publication of results from phase 3 trials of mRNA vaccines, post-marketing evaluation, including those by the US Vaccine Adverse Event Reporting System, provides opportunities to implement vaccine programmes with more precision. As of December, 2021, the omicron variant is spreading rapidly around the world and is set to be the dominant variant globally in early 2022. Consequently, vaccination and booster vaccines will be of considerable importance,
Just as different population groups have been found to be more susceptible to thrombosis with thrombocytopenia syndrome (TTS) after COVID-19 vaccination,
Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines.
different population groups (in our analysis, those of male sex and younger age) are more susceptible to myopericarditis. Just as there are appropriate strategies to address TTS, reasonable policies—such as preferentially offering a non-mRNA vaccine to males, particularly those younger than 18 years—could be considered to manage the risk of myopericarditis, while considering the overall benefits and harms of the vaccines. These policies will become more crucial as more countries begin offering booster doses of COVID-19 vaccines to more people under the age of 30 years. However, the risk and benefit calculations on such policy-making decisions must take into account the local epidemiology (ie, the incidence rate of COVID-19 infection at the time and location that the decision is being made), whether there are other non-mRNA COVID-19 vaccines available, and the risk of morbidity from COVID-19 infection for that particular group, while recognising that such factors and decisions will be dynamic during a pandemic. It is also important to interpret the risks and benefits in the context of the background incidence of myopericarditis across subpopulations—ie, the risk of myopericarditis will depend on the prevailing prevalence of COVID-19 locally and at the time of vaccination.
There are three main strengths of our study. First, with a sample size of more than 400 million vaccine doses, to our knowledge, this study is the largest to quantify the incidence of myopericarditis post-vaccination. Second, we compared the incidence of myopericarditis between COVID-19 and non-COVID-19 vaccines, which gives an indication of whether COVID-19 vaccines increase the rate of myopericarditis compared with other routine non-COVID-19 vaccinations. Third, the analyses between subpopulations within those receiving COVID-19 vaccines help to clarify potential at-risk populations and could contribute to driving better vaccination policy-making decisions.
Nonetheless, we recognise several limitations of our analysis. Most of the studies included in our review did not report on outcomes of patients younger than 12 years receiving vaccination against COVID-19, as vaccination of this younger age group is relatively recent. As such, the findings of our review are not generalisable to children in that age group. Additionally, the comparisons made between COVID-19 and non-COVID-19 vaccines were made indirectly across studies from different time periods. There are far more sensitive tools (eg, MRI, widespread echocardiography, or biopsy) being used currently that did not play as large a role in diagnosing myopericarditis previously in people receiving non-COVID-19 vaccines. This disparity introduces heterogeneity to the reporting and treatment of myopericarditis, which results in potential confounders within our analysis. There are other important vaccines (including, but not limited to, those against hepatitis, Haemophilus influenzae, pneumococcus, and diphtheria, pertussis, and tetanus) that were under-represented in our analysis, suggesting that cases of myopericarditis after these commonly used vaccines occurred very rarely. Furthermore, the 95% CIs for the pooled estimate of non-COVID-19 vaccines were relatively wide, most likely due to two main factors: heterogeneity and variability in the type of vaccine (for which we conducted a subgroup analysis of non-COVID-19 vaccine subtypes to explore as a potential source of heterogeneity), and imprecision resulting from a smaller sample size than that for COVID-19 vaccines. Because COVID-19 vaccines were developed in response to a new global pandemic, they have been administered at an unprecedented rate, with millions of doses given within a short period, unlike any of the comparator non-COVID-19 vaccines. As such, the relative incidence of myopericarditis following COVID-19 vaccination should be interpreted in this context, although it is probably more accurate than the incidence of non-COVID-19 vaccines. Our analysis is also based on study-level data, which limited our analysis of subpopulations. Although we were able to partially account for this by conducting a strata-level meta-regression analysis by age, more granular data are required to better guide the clinical decision-making process. Our analysis also uses data from registries and databases, which are inherently limited by the lack of longitudinal data, and some of the coded cases of myopericarditis might turn out to not have myopericarditis following further investigation of the symptoms. Some studies only reported the number of doses of vaccines that were administered. As a result, we had to analyse the incidence of myopericarditis by doses and not patients. Most of the studies included in our analysis did not report on myocarditis or pericarditis specifically, but grouped both complications under the umbrella term myopericarditis. Nonetheless, these remain the best data available on myopericarditis following vaccination. Additionally, myopericarditis occurring in temporal relation with COVID-19 vaccination cannot always confirm a diagnosis of vaccine-induced myopericarditis, as it is difficult to distinguish it from myopericarditis due to other causes. Finally, our review was unable to account for the disease burden or severity of myopericarditis, which, while usually mild and self-limiting, can take a more fulminant course eventually requiring mechanical circulatory support. There are also other side-effects that were not addressed in this study that might influence a person’s decision to receive a vaccination.
In conclusion, this meta-analysis of more than 400 million doses of vaccines suggests that the overall incidence of myopericarditis following COVID-19 vaccination is similar to that in the published literature on its incidence after influenza vaccination, and is lower than the incidence after live smallpox vaccination. The incidence of myopericarditis in younger males after mRNA COVID-19 vaccination is higher than expected by comparison with other age groups. The scale of mass global vaccination and enhanced surveillance might account for the increased reporting of this adverse event in the context of COVID-19 vaccination. Nonetheless, certain subpopulations—those of male sex or younger age and those receiving an mRNA vaccine, particularly the second dose—appear to be at increased risk of myopericarditis following COVID-19 vaccination. These findings are important additions to the conversation when weighing the risks and benefits of COVID-19 vaccination during this pandemic. Although the results of our analysis place the risks of COVID-19 vaccination into perspective, the decision to vaccinate should be informed by appropriately weighing the benefits and harms of COVID-19 vaccination, the local risk of exposure to COVID-19 infection at the time, and the risk of myopericarditis from COVID-19 infection itself.
KR and RRL designed the study and drafted the manuscript. RRL, KR, and FLT contributed to the search strategy, screening of articles, and data collection. RRL and FLT contributed to the risk of bias assessment and made the tables and figures. RRL, BCT, and KR contributed to data analysis and interpretation. KR, RRL, GM, JS, DF, and BCT contributed to critical revision of manuscript for intellectually important content. All authors provided critical conceptual input, interpreted the data analysis, and read and approved the final draft of the manuscript. RRL, FLT, and KR accessed and verified the data. RRL and KR were responsible for the decision to submit the manuscript for publication.
Partner links
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.